Physician profile
Paramjit Singh Benipal
NPI 1306803572
$2,041.14
in general payments reported to CMS, 2019-2025
15 companies · $441 in 2025
The $441 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2020: $28.46 · 2021: $183 · 2022: $332 · 2023: $346 · 2024: $573 · 2025: $441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,360.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,353.90 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Pfizer INC. | $109.28 | 2019-2025 | |
| Boston Scientific Corporation | $93.81 | 2023-2024 | Resolution 360 Clip |
| Celgene Corporation | $85.41 | 2021-2022 | |
| Gilead Sciences, INC. | $77.28 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.84 | 2021-2024 | Xifaxan |
| Madrigal Pharmaceuticals | $43.73 | 2024-2025 | Rezdiffra, Resmetirom |
| Shionogi INC | $42.63 | 2019 | |
| Janssen Biotech, INC. | $39.68 | 2024 | Stelara, Simponi, Tremfya |
| Organon LLC | $28.35 | 2024 | |
| Ardelyx, INC. | $27.95 | 2022 | |
| Lilly USA, LLC | $26.26 | 2025 | Omvoh |
| Allergan, INC. | $24.62 | 2019 | |
| Qol Medical, LLC | $18.52 | 2024 | Sucraid |
| Mauna Kea Technologies, INC. | $13.88 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paramjit Benipal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.